Testosterone Replacement for Male Opioid Agonist Maintained Patients

Testosterone Replacement for Male Opioid Agonist Maintained Patients

This study is designed to develop an effective treatment intervention for chronic pain, symptomatic hypogonadism, and opioid addiction

This study aims to assess the initial efficacy of testosterone replacement in male opioid agonist patients with symptomatic hypogonadism and chronic pain.

The study has two specific aims:

1. To estimate, in male opioid agonist maintained patients, the prevalence of (a)symptomatic hypogonadism and (b) co-occurring symptomatic hypogonadism and chronic pain.
2. To conduct a pilot randomized clinical trial to obtain data regarding the feasibility, acceptability, and efficacy (compared to waitlist control) of testosterone replacement for male patients with chronic pain and opioid dependence, and symptomatic hypogonadism treated with opioid agonist maintenance treatment (N=40).

Inclusion Criteria:

• Between 18 and 50 years of age
• Male buprenorphine- or methadone-maintained patients at the APT Foundation
• Moderate to severe chronic pain
• Meet criteria for symptomatic hypogonadism
• Understand English
• Interested in receiving testosterone replacement

Exclusion Criteria:

• Current suicide or homicide risk
• Life-threatening or unstable medical condition
• Known or suspected prostate or chest cancer or history of polycythemia